Novo Nordisk's Zenagamtide Shows Strong A1C and Weight Loss Results in Phase 2 Trial
Event summary
- Novo Nordisk's phase 2 trial of zenagamtide showed statistically significant reductions in A1C levels and up to 14.6% weight loss in adults with type 2 diabetes.
- The study met its primary endpoint with all doses of zenagamtide showing a dose-dependent reduction in A1C levels compared to placebo.
- Up to 89.1% of participants on zenagamtide achieved A1C levels below 7%, and up to 76.2% achieved levels at or below 6.5%.
- Novo Nordisk plans to initiate a phase 3 development program for zenagamtide in H2 2026.
The big picture
Novo Nordisk's zenagamtide represents a novel approach in type 2 diabetes treatment by combining GLP-1 and amylin receptor agonism in a single molecule. The phase 2 results underscore the company's leadership in diabetes care and its ability to innovate in a market increasingly focused on combination therapies. With 36–38 million people living with type 2 diabetes in the U.S. alone, the potential for zenagamtide to expand treatment options is significant.
What we're watching
- Clinical Efficacy
- How the significant A1C reductions and weight loss results will position zenagamtide against existing treatments in the type 2 diabetes market.
- Regulatory Pathway
- The pace at which Novo Nordisk can advance zenagamtide through phase 3 trials and potential regulatory approval.
- Market Differentiation
- Whether zenagamtide's dual mechanism of action can sustain its competitive edge in a crowded GLP-1 agonist market.
Related topics